Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Practice Analysis of Care, Paraclinical Exams and Treatments Received by Geriatric Patients Both During the Last Week and the Last 24 Hours of Their Lives.

NCT06026241 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-03-01
Last updated
2025-03-18

Condition(s) studied

End-of-life Care

Investigational drug(s) / intervention(s)

Collecting data from the medical record

Collecting data from the medical record: Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.

Study summary

End-of-life care is a core topic for geriatricians. One of the key aspects of end-of-life management is deciding when to discontinue active care measures (for example blood pressure monitoring, blood tests and X-rays) in favor of exclusive comfort care. In this retrospective observational study, the investigators looked at the care measures, treatments and paraclinical exams received by geriatric patients both one week and 24 hours before their death.

Eligibility

Sex
ALL
Min age
75 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All patients over 75 years old who died in a geriatric short-stay department at Saint-Etienne University Hospital. Exclusion Criteria: \- Patients under 75 years old

Primary outcome measure(s)

  • Prevalence of care and treatments received during the last week of life, and during the last 24 hours of life — In the last week of life and 24 hours before death
    To measure the prevalence of care (hemodynamic, biological and radiological monitoring), and to evaluate the treatments received during the last week of life, and during the last 24 hours of life of patients hospitalized and who died in a geriatric short-stay ward.

Trial sites (1)

FacilityCityRegionStatus
CHU Saint-Etienne Saint-Etienne France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06026241 on ClinicalTrials.gov ↗ ← All trials in France